How New Technologies Can Improve Compliance in Pharmaceutical and Biotech Manufacturing
While U.S. drug products are of high quality, there has been an increasing trend towards manufacturing problems, resulting in recalls, disruption of operations and drug shortages. Companies are missing billions of dollars of potential additional revenue, and necessary medications are sometimes unavailable to the public. By enforcing 21 CFR Part 11 and introducing additional new quality-related initiatives, the FDA is signaling a need for better compliance to ensure consistency and safety. The industry wants to comply, but many manufacturers lack the necessary capabilities, or are unaware that new technologies are available to meet the beefed-up regulatory demands and still operate efficiently and profitably. Justin Neway, Ph.D., executive vice president and chief science officer of Aegis Analytical Corporation examines why these problems occur and how new technology can improve the manufacturing process.